E Fund Management Co. Ltd. Invests $334,000 in Solventum Co. (NYSE:SOLV)

E Fund Management Co. Ltd. purchased a new position in Solventum Co. (NYSE:SOLV) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 5,063 shares of the company’s stock, valued at approximately $334,000.

Several other large investors have also recently modified their holdings of the stock. Candriam S.C.A. purchased a new position in Solventum in the 4th quarter worth about $517,000. Raymond James Financial Inc. purchased a new stake in shares of Solventum during the 4th quarter valued at about $18,583,000. Arizona State Retirement System increased its position in shares of Solventum by 1.4% during the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the company’s stock valued at $2,817,000 after purchasing an additional 580 shares during the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of Solventum during the 4th quarter valued at about $1,545,000. Finally, Atria Investments Inc increased its position in shares of Solventum by 5.6% during the 4th quarter. Atria Investments Inc now owns 12,357 shares of the company’s stock valued at $816,000 after purchasing an additional 658 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on SOLV shares. Bank of America upped their price target on shares of Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday, February 26th. Mizuho boosted their price objective on Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, March 3rd. Wells Fargo & Company boosted their price objective on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. Morgan Stanley boosted their price objective on Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research note on Wednesday. Finally, The Goldman Sachs Group boosted their price objective on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $79.86.

Solventum Stock Up 2.9 %

NYSE SOLV opened at $77.96 on Friday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The company has a market capitalization of $13.47 billion and a P/E ratio of 28.35. Solventum Co. has a one year low of $47.16 and a one year high of $85.92. The stock has a 50 day moving average price of $73.65 and a 200-day moving average price of $70.63.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.